NCT02269995View on ClinicalTrials.gov

Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma

CompletedOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

March 6, 2014

Primary Completion Date

May 14, 2015

Study Completion Date

December 25, 2015

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE

E7040

E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .

Trial Locations (1)

Unknown

Multiple Locations

All Listed Sponsors

lead

Eisai Co., Ltd.

INDUSTRY

NCT02269995 - Post-marketing Surveillance of DC Bead in Patients With Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter